Post-anlotinib treatment showed that miR-1244 expression levels increased, p53 and p21 expressions were up-regulated, while CCNE2 and CDK2 were down-regulated, indicating tumor-suppressive functions (Fig. 6F and S8B). Here, CDK2 is linked to neoplasm.